<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852198</url>
  </required_header>
  <id_info>
    <org_study_id>FZ2022</org_study_id>
    <secondary_id>NL74137.018.20</secondary_id>
    <nct_id>NCT04852198</nct_id>
  </id_info>
  <brief_title>Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial</brief_title>
  <acronym>Roux-en-WHY?</acronym>
  <official_title>A Study on Safety and Efficacy Comparing 150cm One Anastomosis Gastric Bypass With 150cm Biliopancreatic Limb Roux-en-Y Gastric Bypass (Roux-en-WHY?): An Open Label, Multicentre Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flevoziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flevoziekenhuis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficiency of OAGB compared to RYGB&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: to compare two different types of gastric bypass operations on surgical outcome.&#xD;
&#xD;
      Objective: to compare two established procedures in order to find the optimal procedure in&#xD;
      terms of weight loss and metabolic control that is associated with the fewest side-effects&#xD;
      and complications, and decreased invasiveness.&#xD;
&#xD;
      Study design: A multicentre, open label, non-inferiority randomized controlled trial Study&#xD;
      population: Patients are eligible for inclusion if their body-mass index (BMI) was 40 kg/m2&#xD;
      or higher, or 35 kg/m2 or higher with the presence of at least one comorbidity (type 2&#xD;
      diabetes, high blood pressure, obstructive sleep apnoea, dyslipidaemia, osteoarthritis of the&#xD;
      hip or knee) and a positive evaluation by our bariatric multidisciplinary team (BMDT) and are&#xD;
      aged 18-65.&#xD;
&#xD;
      Intervention: Group 1: One Anastomosis Gastric Bypass with 150cm biliopancreatic limb. Group&#xD;
      2: Roux-en-Y gastric bypass with biliopancreatic limb of 150cm and 75cm alimentary limb.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      % Excess BMI loss at two years&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Metabolic status Nutritional status Comorbidity remission QOL Complications or serious&#xD;
      adverse events (SAE's)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial with 2 groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage excess BMI loss at 2 years (%EBMIL)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage excess BMI loss after 2 years of follow-up</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Obesity</condition>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>OAGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OAGB</intervention_name>
    <description>Simplified gastric bypass procedure</description>
    <arm_group_label>OAGB</arm_group_label>
    <other_name>Mini gastric bypass</other_name>
    <other_name>Omega loop gastric bypass</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RYGB</intervention_name>
    <description>Roux-en-Y gastric bypass. Standard procedure in the Netherlands</description>
    <arm_group_label>RYGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body-mass index (BMI) of 40 kg/m2 or higher, or 35 kg/m2 or higher with the presence&#xD;
             of at least one comorbidity (type 2 diabetes, high blood pressure, obstructive sleep&#xD;
             apnoea, dyslipidaemia, osteoarthritis of the hip or knee)&#xD;
&#xD;
          -  a positive evaluation by our BMDT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of H. Pylori, resistant to eradication therapy&#xD;
&#xD;
          -  chronic diarrhoea&#xD;
&#xD;
          -  history of previous bariatric or extensive abdominal surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stef JM Smeets, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flevoziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stef JM Smeets, MD PhD</last_name>
    <phone>0031368688888</phone>
    <email>ssmeets@flevoziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Floris Bruinsma, Student</last_name>
    <phone>0031368688888</phone>
    <email>fbruinsma@flevoziekenhuis.nl</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

